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Background: Circulating tumors cells (CTCs) are considered an early step towards
metastasis and have been linked to poor prognosis in several types of cancer. CTCs
in squamous cell carcinoma of the head and neck (SCCHN) have an unclear role.
Methods: In this prospective study, patients with locally advanced or metastatic
SCCHN had CTC counts assessed before starting systemic treatment using the Cel-
lSearch System. Select cases also had sequential CTC evaluation. Presence of CTCs
was correlated with patient characteristics and outcomes.
Results: Forty-eight patients enrolled, and 36 had evaluable clinical data and baseline
CTC counts. Twenty-five patients had locally advanced disease (LAD) and 11 had
metastatic disease. ≥1 CTCs were detected in six patients with LAD (24%) and four
with metastatic disease (36%). On univariate analysis, smoking was associated
with CTCs.
Conclusion: CTCs are not associated with prognosis in patients with LAD and meta-
static disease; however, they are present in this patient population, and ≥1 CTCs is
associated with a history of smoking.
Level of evidence: 1b; individual prospective cohort study.
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1 | INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) accounts for
approximately 5% of newly diagnosed cancer cases, equaling roughly
644 000 cases and over 350 000 cancer deaths worldwide each
year.1,2 Patients typically present with locoregionally advanced dis-
ease (LAD), and prognosis is associated with age, human
papillomavirus (HPV) status, smoking or alcohol history, and lymph
node involvement.3 Despite advances in the treatment for these
patients, long-term disease-free and overall survival remains poor—
approximately 40% to 60% of patients develop local recurrences and
20% to 30% are diagnosed with metastatic disease.1,2
Circulating tumor cells (CTCs) and their clusters, circulating tumor
microemboli (CTM), (defined as ≥3 CTCs) are detached tumor cells
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from the primary or metastatic sites that infiltrate into the lymphatic
and circulatory system. In the context of localized disease, CTCs and
CTMs are considered an early step towards metastatic spread. When
present in peripheral blood, they correlate with poor prognoses in
breast, gastric, and prostate cancer.4-8
In patients with regionally advanced or metastatic SCCHN, CTCs
have been found in 18% to 33% of patients9,10; other studies have
demonstrated that CTCs are found independently of T-stage and HPV
status.11,12 However, CTCs have an unclear impact on prognosis.
Some studies have reported that CTCs correlate with reduced
disease-free survival, progression-free survival (PFS) and overall sur-
vival (OS),10,13,14 including one study of 53 patients with recurrent or
metastatic SCCHN that found CTCs were associated with lower PFS
and OS.10 Another study of 73 patients with LAD found that a
decrease in CTC count during treatment suggested nonprogressive
disease.15 Others have found that CTCs did not correlate to out-
comes.9,16 More research is needed to clarify the prognostic value of
CTCs in SCCHN, which is the goal of this study.
In this prospective pilot study, we enrolled 48 patients with
locally advanced or metastatic SCCHN and collected peripheral blood
samples before starting systemic treatment. Select patients also had
sequential blood draws. Patients had samples analyzed by CellSearch,
which uses upregulated epithelial cell adhesion molecule (EpCAM) to
identify potential CTCs and further stratifies them based on cellular
markers. We used this technology as it is established that EpCAM is
upregulated in many carcinomas, including SCCHN.17,18
2 | METHODS
2.1 | Patient eligibility and demographics
The Institutional Review Board at Dana-Farber/Brigham and
Women's Cancer Center approved the research protocol, and all
accrued patients signed written informed consent prior to enrollment.
Eligible patients had pathologically confirmed SCCHN and
locoregionally advanced or distant metastatic (stage III or IV, AJCC
seventh edition) disease by imaging, were receiving treatment at
Dana-Farber Cancer Institute (DFCI), and had an Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or less. Patients
treated outside of DFCI or without tumor tissue available were
excluded from the study.
Prior to enrollment, patients who consented to the study had pre-
viously been assigned treatment by their treating oncologists to one
of three regimens: sequential induction followed by
chemoradiotherapy (CRT), concurrent CRT, or systemic treatment for
distant metastatic disease, which were also the three cohorts in this
study. Blood samples were collected based on cohort: patients with
LAD and metastatic cancer had 7.5 mL of whole blood collected
before starting treatment. Some patients also had sequential blood
draws throughout treatment and during follow-up. Patient demo-
graphics were collected and deidentified, and subjects were followed
for PFS and OS. PFS is the time from initiation of treatment to disease
progression or loss to follow-up, and OS is the time from initiation of
treatment to death or loss to follow-up. Disease burden was assessed
using clinical notes and imaging studies taken for standard of
treatment.
2.2 | Isolation and enumeration of CTCs
Blood samples were collected before, during, and after treatment.
Fresh, unrefrigerated peripheral blood samples were processed within
96 hours of collection using the CellSearch System (Huntingdon
Valley, Pennsylvania). Briefly, samples were immunomagnetically
enriched for CTCs with anti-EpCAM conjugated magnetic beads and
subsequently stained with immunofluorescent antibodies to
cytokeratins 8, 18, and 19 and CD45 and a 40,6-diamidino-2-phenyl-
indole (DAPI) nuclear stain. Carcinoma cells were identified in a semi-
automated fashion as cells positive for cytokeratin, negative for
CD45, and fulfilling the predefined morphologic criteria of the food
and drug administration (FDA)-cleared in vitro diagnostic test. All sam-
ples were reviewed by a trained pathologist (A. C. L.). Results were
reported in number of CTCs identified per 7.5 mL of whole blood.
2.3 | Statistical analysis
Fisher's exact tests, likelihood ratios, and Mann-Whitney U tests were
used in univariate analysis to determine factors associated with pres-
ence of CTCs. Statistical analyses were performed using SPSS version
24 (IBM; Armonk, NY).
3 | RESULTS
Forty-eight patients were enrolled, but one patient had inaccessible
medical records and was not included in analysis. Forty-seven patients
(44 men, 3 women), with a median age of 55.5 (24-66), enrolled from
October 2011 to October 2015. Of those with known HPV status, 30
patients had HPV (+) disease and 5 had HPV (−) disease. Twenty-
three patients had a significant alcohol use history, defined as ≥5
drinks/week, and 20 had a significant smoking history, defined as ≥10
pack-years. Thirty-three patients had LAD, and most received cisplatin
or carboplatin with definitive intensity modulated radiation therapy
for their initial treatment (n = 31). Fourteen patients had metastatic
disease and received varying systemic treatment regimens (Table 1).
The median follow-up was 35.5 months for the cohort.
Of the 47 patients, 36 (75%) had a successful CTC assessment
prior to the start of treatment and clinical data; 8 patients never
underwent CTC draw, 1 patient withdrew consent from the study
prior to capturing outcome data, and two patients had incomplete
CTC analysis due to poor sample quality and CellSearch failure,
respectively. Twenty-five patients had LAD and 11 had metastatic dis-
ease. Most patients had primary lesions in the oropharynx (n = 23)
and HPV (+) disease (n = 23). In this cohort, 19 patients had a smoking
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history <10 pack years, and 19 had <5 alcoholic drinks/week. Baseline
CTCs were detected in six patients with LAD and four with metastatic
disease and had varying amounts (range = 1-9). Primary location, T-
stage, N-stage, disease burden, HPV association, median PFS, and
median OS were not associated with ≥1 CTCs. Significant smoking
history (P = .002) was associated with ≥1 CTCs—10 patients had
detectable CTCs at baseline and 9 had a significant smoking history
(Table 2). Of these nine patients, three patients also had a significant
alcohol history. Comparing LAD and metastatic SCCHN PFS and OS
with CTCs did not demonstrate a significant correlation (Table 3).
Separately, 18 patients had sequential CTC blood draws at base-
line and during or after treatment. Eleven patients never had ≥1 CTCs,
while seven did. Of the seven patients, three patients had CTCs
detected once, while four patients had CTCs detected more than
once. Timing of blood draws and number (range: 2-12) varied. Neither
median PFS nor OS were significantly associated with CTCs (Table 4).
Within this cohort, three patients had CTMs; one patient had CTMs
during treatment, and two patients had CTMs before treatment. The
two patients who had CTMs before treatment had metastatic disease
and CTCs ≥2 at multiple time points. The patients died 2 and 6 months
after the baseline draw, respectively. Notably, the former patient had
170 CTCs 4 days before death.
4 | DISCUSSION
We conducted a prospective pilot study investigating the effect of
CTCs on PFS and OS in patients with locally advanced or metastatic
TABLE 1 Consented patient characteristics
All patientsa
(%) (n = 47)
Induction arm
(%) (n = 15)
CRT arm
(%) (n = 18)
Metastatic arm
(%) (n = 14)
Median age at blood draw (range), y 55.0 (24-72) 55 (24-66) 52 (30-72) 60.5 (50-68)
Gender
Male 44 (93.6%) 13 (86.7%) 17 (94.4%) 14 (100.0%)
Female 3 (6.4%) 2 (13.3%) 1 (5.6%) 0 (0.0%)
HPV statusb
Positive 30 (85.7%) 12 (92.3%) 10 (90.9%) 8 (72.7%)
Negative 5 (14.3%) 1 (7.7%) 1 (9.1%) 3 (27.3%)
Smoking historyc
<10 pack-years 26 (56.5%) 9 (60.0%) 12 (70.6%) 5 (35.7%)
≥10 pack-years 20 (43.5%) 6 (40.0%) 5 (29.4%) 9 (64.3%)
Alcohol historyd
≥5 drinks/wk 23 (52.3%) 8 (57.1%) 7 (41.2%) 8 (61.5%)
<5 drinks/wk 21 (47.7%) 6 (42.9%) 10 (58.8%) 5 (38.5%)
Most recent systemic treatment prior to CTC draw
Cisplatin 19 (40.4%) 3 (20.0%) 15 (83.3%) 1 (7.1%)
Carboplatin 15 (31.9%) 10 (66.7%) 3 (16.7%) 2 (14.3%)
Cetuximab and carboplatin 2 (4.3%) 2 (13.3%) - -
Nivolumab 2 (4.3%) - - 2 (14.3%)
Pembrolizumab 2 (4.3%) - - 2 (14.3%)
EXTREME 1 (2.1%) - - 1 (7.1%)
Cetuximab and gemcitabine 1 (2.1%) - - 1 (7.1%)
5-FU and leucovorin 1 (2.1%) - - 1 (7.1%)
Vinorelbine 1 (2.1%) - - 1 (7.1%)
Taxotere 1 (2.1%) - - 1 (7.1%)
Gemcitabine 1 (2.1%) - - 1 (7.1%)
Cetuximab 1 (2.1%) - - 1 (7.1%)
Median follow-up time from study entry
(range), mo
35.5 (2-71) 58 (13-71) 39.0 (4-64) 6 (2-20)
Abbreviations: 5-FU, 5-fluorouracil; CRT, concurrent radiotherapy; CTC = circulating tumor cells; HPV, human papillomavirus.
aOne patient had an inaccessible medical record and was excluded from analysis.
bA total of 12 patients (2 patients in induction arm, 7 patients in CRT arm, and 3 patients in metastatic arm) had unknown HPV status.
cOne patient in the CRT arm had unknown smoking history.
dA total of three patients (one patient in induction arm, one patient in CRT arm, and one patient in metastatic arm) had unknown alcohol history.
HARRIS ET AL. 1065
TABLE 2 Factors associated with
baseline CTCs
0 CTCs (%) (n = 26) ≥ 1 CTCs (%) (n = 10) P value
Primary tumor location
Oropharynx 19 (73.1%) 4 (40.0%) .119
Other 7 (26.9%) 6 (60.0%)
T staginga
T1 5 (20.8%) 2 (25.0%) .449
T2 6 (25.0%) 4 (50.0%)
T3 9 (37.5%) 1 (12.5%)
T4 4 (16.7%) 1 (12.5%)
N stagingb
<N2b 7 (26.9%) 1 (14.3%) .652
≥N2b 19 (73.1%) 6 (85.7%)
Disease burden at time of draw
LAD 19 (73.1%) 6 (60.0%) .454
Metastatic disease 7 (26.9%) 4 (40.0%)
HPV statusc
Positive 18 (85.7%) 5 (83.3%) 1
Negative 3 (14.3%) 1 (16.7%)
Smoking history
<10 pack-years 18 (69.2%) 1 (10.0%) .002
≥10 pack-years 8 (30.8%) 9 (90.0%)
Alcohol historyd
<5 drinks/wk 15 (62.5%) 4 (40.0%) .276
≥5 drinks/wk 9 (37.5%) 6 (60.0%)
Median OSe (range), mo 32.10 (3-72) 30.30 (1-70) .337
Median PFSf (range), mo 28.00 (1-71) 28.00 (1-70) .614
Abbreviations: CTC, circulating tumor cells, HPV, human papillomavirus; LAD, locally advanced disease;
OS, overall survival, PFS, progression-free survival.
aTwo patients in the “0 CTCs” group and two patients in the “CTCs observed” group had unknown T-
staging.
bThree patients in the “≥1 CTCs group” had unknown N staging.
cFive patients in the “0 CTCs” group and four patients in the “CTCs observed” group had unknown HPV
status.
dTwo patients in the “0 CTCs” group had unknown alcohol history.
ePFS is until disease progression or last available follow-up.
fOS is until death or last available follow-up.
TABLE 3 Disease burden at time of
baseline CTC draw vs PFS and OS
Locally advanced disease 0 CTCs (n = 19) ≥1 CTCs (n = 6) P value
Median PFSa (range), mo 41.00 (4-71) 38.50 (25-69) .975
Median OSb (range), mo 44.40 (5-72) 40.30 (26-70) .555
Metastatic disease 0 CTCs (n = 7) ≥1 CTCs (n = 4) P value
Median PFSa (range), mo 4.00 (1-7) 2.50 (1-19) .927
Median OSb (range), mo 11.13 (3-21) 5.37 (1-19) .412
Abbreviations: CTC, circulating tumor cells; OS, overall survival; PFS, progression-free survival.
aPFS is until disease progression or last available follow-up.
bOS is until death or last available follow-up.
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SCCHN. Forty-eight patients enrolled in this study and 36 patients
had evaluable CTCs with correlating clinical data. Of the 36 patients,
CTCs were detected in six patients with LAD and four patients with
metastatic disease (24% and 36%, respectively). A significant smoking
history was associated with CTCs on univariate analysis, while tumor
stage and other known prognostic markers were not.
CTCs have been studied in various cancers, and these studies sug-
gest that increased CTCs are associated with a poorer prognosis. In
breast cancer, CTC-positive patients (≥5 CTCs/7.5 mL) have decreased
PFS and OS,19 and in a study of 216 patients with ovarian cancer, ≥2
CTCs at baseline predicted increased risk for both progression and
death.20 The majority of findings in lung cancer that analyzed CTCs
using CellSearch, both in nonsmall cell lung cancer and small cell lung
cancer, have found that increased CTCs predict poorer prognosis.21
Thus far, few studies have been published about the impact of CTCs
in head and neck cancer. One study of 53 patients with recurrent/meta-
static head and neck cancer stratified patients with ≥2, 1, and 0 CTCs at
baseline, and found a significant difference in PFS and OS between the
cohorts.10 Similar to breast cancer, ovarian cancer, and other cancers,
increased CTCs seem to predict a worse prognosis, although this must
be validated in SCCHN. In our cohort, we had two patients with ≥2
detectable CTCs at multiple time points, with one patient surviving for
2 months and having 170 CTCs 4 days before death.
This study found that smoking is positively associated with CTC
detection on univariate analysis. Smoking has many effects on cell-
to-cell adhesion, including downregulating E-cadherin, a tumor sup-
pressor that maintains cell-cell adhesion, and promoting epithelial to
mesenchyme transition (EMT)22-29 in various cancers including pros-
tate, lung, and oropharyngeal squamous cell carcinoma.26,30-32 More-
over, a key step in EMT is loss of E-cadherin, leading to invasive
behavior and metastasis. Tobacco smoke plays a role in this patho-
genesis in SCCHN by causing hypermethylation of E-cadherin's pro-
moter33 and dysregulating microRNA profiles,34 although more
mechanisms have been described in lung cancer.23 The majority of
patients in this study were also HPV16 (+) which transcriptionally
represses E-cadherin.32,35 EMT promotes CTC formation,36 thus the
patients in this study had risk factors that facilitate the generation
of CTCs.
In previous studies, smoking and presence of CTCs in SCCHN has
not demonstrated an association: one study of 144 patients compared
current smokers and nonsmokers and found no association, and
another study of 48 patients did not find significance in patients with
a ≥15 pack-year.14,37 These studies used different methodologies for
detecting CTCs, but in patients with lung cancer who had CTC
detection by CellSearch, smoking was similarly found not to be associ-
ated with smoking.38,39 Although these are contradictory to our find-
ings, they suggest that the differences in detection methods and
carcinoma contribute to the variability.
The lack of association with PFS and OS in this study raises
the question as to whether CellSearch in SCCHN selects the most
prognostic population. Recently, new technologies have allowed
detection of CTCs that are not dependent on EpCAM and have
shown promise.40 With the current data available on CellSearch on
patients with SCCHN, it seems that other modalities should be
examined. Moreover, Nicolazzo et al describe the challenges with
CellSearch and how subpopulations of CTCs with lower expression
levels of EpCAM are worth investigating, especially since CTCs
from patients with SCCHN detected by CellSearch do not have
prognostic value.41
This study had limitations—our low enrollment and heterogene-
ity of disease weaken our conclusions. Also, treatment was not stan-
dardized within cohorts. Additionally, some patients had more
sequential blood draw results than others, and several patients did
not meet the endpoints of the study. Timing of blood draws in rela-
tion to treatment may have played a role in the differences in CTC
counts.
Our data suggest that smoking may play a role in CTC develop-
ment in patients with SCCHN. A homogenous study cohort with stan-
dardized care, increased enrollment, and regularization of blood draws
during and after treatment might have allowed us to establish associa-
tion between CTC and other factors more firmly, and we therefore
suggest further investigation to assess efficacy and predictive value of
CTCs in this patient population.
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TABLE 4 CTCs in patients with sequential draws vs PFS and OS
0 CTCs (n = 11) ≥1 CTCs (n = 7) P value
Median PFSa (range), mo 31.00 (1-71) 13.00 (1-69) .126
Median OSb (range), mo 60.73 (3-72) 13.73 (1-70) .285
Abbreviations: CTC, circulating tumor cells; OS, overall survival; PFS, progression-free survival.
aPFS is until disease progression or last available follow-up.
bOS is until death or last available follow-up.
HARRIS ET AL. 1067
REFERENCES
1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data
Visualizations Tool, based on november 2017 submission data
(1999–2015). U.S. Department of Health and Human Services
CfDCaPaNCI, trans. Atlanta, GA, USA: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention
and National Cancer Institute; 2018. https://gis.cdc.gov/Cancer/
USCS/DataViz.html.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global can-
cer statistics. CA Cancer J Clin. 2011;61(2):69-90.
3. Osazuwa-Peters N, Adjei Boakye E, Chen BY, Tobo BB, Varvares MA.
Association between head and neck squamous cell carcinoma sur-
vival, smoking at diagnosis, and marital status. JAMA Otolaryngol Head
Neck Surg. 2018;144(1):43-50.
4. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. New Engl J Med.
2004;351(8):781-791.
5. Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P,
Nanus DM. Circulating tumor cells in prostate cancer diagnosis and
monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18
(4):389-402.
6. Giordano A, Egleston BL, Hajage D, et al. Establishment and validation
of circulating tumor cell-based prognostic nomograms in first-line
metastatic breast cancer patients. Clin Cancer Res. 2013;19(6):1596-
1602.
7. Tsai W-S, Chen J-S, Shao H-J, et al. Circulating tumor cell count cor-
relates with colorectal neoplasm progression and is a prognostic
marker for distant metastasis in non-metastatic patients. Sci Rep.
2016;6:24517.
8. Zou K, Yang S, Zheng L, Wang S, Xiong B. Prognostic role of the circu-
lating tumor cells detected by cytological methods in gastric Cancer: a
meta-analysis. Biomed Res Int. 2016;2016:10.
9. Bozec A, Ilie M, Dassonville O, et al. Significance of circulating tumor
cell detection using the CellSearch system in patients with locally
advanced head and neck squamous cell carcinoma. Eur Arch
Otorhinolaryngol. 2013;270(10):2745-2749.
10. Grisanti S, Almici C, Consoli F, et al. Circulating tumor cells in patients
with recurrent or metastatic head and neck carcinoma: prognostic
and predictive significance. PloS One. 2014;9(8):e103918.
11. Kawada T, Takahashi H, Sakakura K, et al. Circulating tumor cells in
patients with head and neck squamous cell carcinoma: feasibility of
detection and quantitation. Head Neck. 2017;39(11):2180-2186.
12. Wu X-L, Tu Q, Faure G, Gallet P, Kohler C, Bittencourt MDC. Diag-
nostic and prognostic value of circulating tumor cells in head and
neck squamous cell carcinoma: a systematic review and meta-analy-
sis. Sci Rep. 2016;6:20210-20210.
13. Inhestern J, Oertel K, Stemmann V, et al. Prognostic role of circulating
tumor cells during induction chemotherapy followed by curative sur-
gery combined with postoperative radiotherapy in patients with
locally advanced Oral and Oropharyngeal squamous cell Cancer. PLoS
One. 2015;10(7):e0132901-e0132901.
14. Jatana KR, Balasubramanian P, Lang JC, et al. Significance of circulat-
ing tumor cells in patients with squamous cell carcinoma of the head
and neck: initial results. Arch Otolaryngol Head Neck Surg. 2010;136
(12):1274-1279.
15. Buglione M, Grisanti S, Almici C, et al. Circulating tumour cells in
locally advanced head and neck cancer: preliminary report about their
possible role in predicting response to non-surgical treatment and
survival. Eur J Cancer. 2012;48(16):3019-3026.
16. Winter SC, Stephenson S-A, Subramaniam SK, et al. Long term
survival following the detection of circulating tumour cells in
head and neck squamous cell carcinoma. BMC Cancer. 2009;9:
424-424.
17. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the
17–1A antigen (Ep-CAM). J Mol Med. 1999;77(10):699-712.
18. Schnell U, Cirulli V, Giepmans BNG. EpCAM: structure and function
in health and disease. Biochim Biophysica Acta Biomembr. 2013;1828
(8):1989-2001.
19. Moussavi-Harami SF, Wisinski KB, Beebe DJ. Circulating tumor cells
in metastatic breast Cancer: a prognostic and predictive marker.
J Patient Center Res Rev. 2014;1(2):85-92.
20. Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells pre-
dict progression free survival and overall survival in patients with
relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011;
122(3):567-572.
21. Kapeleris J, Kulasinghe A, Warkiani ME, et al. The prognostic role of
circulating tumor cells (CTCs) in lung cancer. Front Oncol. 2018;8:
311-311.
22. Scott DA, Palmer RM. The influence of tobacco smoking on adhesion
molecule profiles. Tobacco Induc Dis. 2002;1(1):7-25.
23. Vu T, Jin L, Datta PK. Effect of cigarette smoking on epithelial to mes-
enchymal transition (EMT) in lung cancer. J Clin Med. 2016;5(4):44.
24. White FHGK. A qualitative ultrastructural study of the intercellular
spaces between epithelial cells treated in vivo with DMBA. J Oral Pat-
hol Med. 1984;13(3):231–243.
25. Tachikawa TKY, Matsui Y, Yoshiki S. In vitro early changes in inter-
cellular junctions by treatment with a chemical carcinogen. Carcino-
genesis. 1986;7(6):885-892.
26. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss
of E-cadherin promotes metastasis via multiple downstream tran-
scriptional pathways. Cancer Res. 2008;68(10):3645-3654.
27. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion mole-
cule (Ep-CAM) modulates cell-cell interactions mediated by classic
cadherins. J Cell Biol. 1997;139(5):1337-1348.
28. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis.
Clin Transl Med. 2015;4:6-6.
29. Hou W, Hu S, Li C, et al. Cigarette smoke induced lung barrier dys-
function, EMT, and tissue remodeling: a possible link between COPD
and lung Cancer. Biomed Res Int. 2019;2019:2025636.
30. Yang S, Long M, Tachado SD, Seng S. Cigarette smoke modulates
PC3 prostate cancer cell migration by altering adhesion molecules
and the extracellular matrix. Mol Med Rep. 2015;12(5):6990-6996.
31. Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK. Smoking
induces epithelial-to-mesenchymal transition in non-small cell lung
cancer through HDAC-mediated downregulation of E-cadherin. Mol
Cancer Ther. 2012;11(11):2362-2372.
32. Lefevre M, Rousseau A, Rayon T, et al. Epithelial to mesenchymal
transition and HPV infection in squamous cell oropharyngeal carcino-
mas: the papillophar study. Br J Cancer. 2017;116:362-369.
33. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M,
Kelsey KT. Patterns of gene promoter methylation in squamous cell
cancer of the head and neck. Oncogene. 2002;21(27):4231-4236.
34. Yu MA, Kiang A, Wang-Rodriguez J, et al. Nicotine promotes acquisi-
tion of stem cell and epithelial-to-mesenchymal properties in head
and neck squamous cell carcinoma. PLoS One. 2012;7(12):e51967-
e51967.
35. D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM,
Hibma MH. Transcriptional repression of E-cadherin by human papil-
lomavirus type 16 E6. PLoS One. 2012;7(11):e48954-e48954.
36. Jie X-X, Zhang X-Y, Xu C-J. Epithelial-to-mesenchymal transition, cir-
culating tumor cells and cancer metastasis: mechanisms and clinical
applications. Oncotarget. 2017;8(46):81558-81571.
37. Tinhofer I, RK CS, Raguse J-D, et al. Detection of circulating tumor
cells for prediction of recurrence after adjuvant chemoradiation in
locally advanced squamous cell carcinoma of the head and neck. Ann
Oncol. 2014;25(10):2042-2047.
38. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor
cells and circulating tumor DNA in non-small cell lung cancer: associa-
tion with clinical endpoints in a phase II clinical trial of pertuzumab
and erlotinib. Clin Cancer Res. 2012;18(8):2391-2401.
1068 HARRIS ET AL.
39. Lindsay CR, Faugeroux V, Michiels S, et al. A prospective examination
of circulating tumor cell profiles in non-small-cell lung cancer molecu-
lar subgroups. Ann Oncol. 2017;28(7):1523-1531.
40. Bankó P, Lee SY, Nagygyörgy V, et al. Technologies for circulating tumor
cell separation from whole blood. J Hematol Oncol. 2019;12(1):48.
41. Nicolazzo C, Gradilone A, Loreni F, Raimondi C, Gazzaniga P. EpCAM
(low) circulating tumor cells: gold in the waste. Dis Markers. 2019;
2019:1718920.
How to cite this article: Harris EJ, Huang J, Carroll E, et al.
Circulating tumor cell analysis in locally advanced and
metastatic squamous cell carcinoma of the head and neck.
Laryngoscope Investigative Otolaryngology. 2020;5:1063–1069.
https://doi.org/10.1002/lio2.448
HARRIS ET AL. 1069
